Evidence map›Paper›PMID 42174096›Full record

ArticleScientific reports2026

Changes in hepatic L-carnitine levels in people with metabolic dysfunction-associated steatotic liver disease (MASLD) assessed by magnetic resonance techniques.

Dragana Savic, Michael Pavlides, Mette Skalshøi Kjær, Sher May Ng, Katharine Thomas, Tim James, Gabrielle Allen, Claire Hart, Stefan Neubauer, Leanne Hodson and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dragana Savic *The Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Radcliffe Department of Medicine, Level 0, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, OX3 9DU, UK.
Michael Pavlides *The Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Radcliffe Department of Medicine, Level 0, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, OX3 9DU, UK.
Mette Skalshøi KjærNovo Nordisk A/S, Copenhagen, Denmark.
Sher May NgThe Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Radcliffe Department of Medicine, Level 0, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, OX3 9DU, UK.
Katharine ThomasThe Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Radcliffe Department of Medicine, Level 0, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, OX3 9DU, UK.
Tim JamesDepartment of Clinical Biochemistry, Oxford University Hospitals NHS Foundation, Oxford, UK.
Gabrielle AllenDepartment of Clinical Biochemistry, Oxford University Hospitals NHS Foundation, Oxford, UK.
Claire HartDepartment of Clinical Chemistry, Sheffield Children's Hospital NHS Foundation, Sheffield, UK.
Stefan NeubauerThe Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Radcliffe Department of Medicine, Level 0, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, OX3 9DU, UK.
Leanne HodsonOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
Ladislav ValkovičThe Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Radcliffe Department of Medicine, Level 0, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, OX3 9DU, UK. ladislav.valkovic@cardiov.ox.ac.uk.
Ferenc E MózesThe Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Radcliffe Department of Medicine, Level 0, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, OX3 9DU, UK.

Funding

British Heart Foundation FS/15/56/31645 and FS/SBSRF/21/31013Slovak Grant Agency APVV #21-0299Slovak Grant Agency VEGA 2/0004/23Wellcome TrustWellcome Trust 221805/Z/20/Z
6 · The paper itself

Abstract

L-carnitine is critical for metabolism of some fatty acids therefore different carnitine species may play a role in metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis. Until recently, hepatic acetylcarnitine could not be quantified non-invasively. Now new technical developments in magnetic resonance spectroscopy (MRS) enable quantification of hepatic acetylcarnitine content in vivo. The aim of this study was to evaluate potential metabolic changes in healthy volunteers and patients with different stages of MASLD before and after a single injection of L-carnitine. This prospective study recruited 10 healthy volunteers and 17 patients (11 with low-risk MASLD, 6 with high-risk MASLD) who underwent cardiac and hepatic MRI and MRS for hepatic acetylcarnitine quantification at baseline and 2 h after injecting 50 mg/kg body weight L-carnitine. Serum samples were obtained for biomarker measurement. A single injection of L-carnitine significantly elevated hepatic acetylcarnitine levels in healthy volunteers (Δ

Indexed as

CarnitineFatty LiverLiverNon-alcoholic Fatty Liver DiseaseAcetylcarnitineAdultAgedBiomarkersCase-Control StudiesFemaleHumansMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMaleMiddle AgedProspective StudiesAcetylcarnitineBiomarkersCarnitine

Identifiers

PMID42174096
PMCPMC13407869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.